

Preliminary Agenda

Join the meeting with Zoom

<https://who.zoom.us/j/91968326081>

Passcode: GDG*Nov23

Time	Day 1 - Tuesday, 28 November	Working material	Presenter
9.00	Opening and welcoming		Ibrahima Soce Fall (TBC)/D. Dagne
9.10	Introductions/ conflicts of interest (Dol) / confidentiality agreement / Nomination of chair, co-chair and rapporteur		S. Jain
9.30	WHO Guidelines development process / Methodology of the meeting	- WHO Handbook for guideline development – 2nd ed. ¹	GRC secretariat (TBC)
10.00	Current treatment guidelines for VL and PKDL case management, efficacy, safety, coverage, logistics, costs, public health implications	- Control of the leishmaniasis: WHO TRS N°949 ²	S. Jain
10.30	Coffee break		
10.45	PKDL Treatment in South Asia-multicentric clinical trial results		Clinical trial experts
11.15	Q & A		
11:45	Investigation report and outcome of WHO Advisor Committee on Safety of Medicinal Products (ACSoMP) on Miltefosine safety		Update from WHO secretariat
12.00	Lunch break		
13:00	GRADE methodology		E. AKI (Co-Chair)
13.30	PICO 1: Systematic review and grading of evidence- methodology and results	- Systematic review report	Cochrane Evidence Review Group
14.00	Findings from the qualitative study		Gladys Honnein
14.30	PICO 1: E-t-D: PKDL treatment in South-East Asia	- All the documents referred to above	E. AKI (Co-Chair)
15.30	Coffee break		
15.45	PICO 1 (Contd.)	As above	Chair, Co-Chair & GDG
17.15	Summary		Chair , Co-Chair

Time	Day 2 – Wednesday, 29 November	Working material	Presenter
9.00	PICO 1 (Contd.) - Any pending issues to be discussed	All the documents referred	Chair, Co-Chair & GDG
9.15	PKDL Treatment in East Africa-clinical trial results		Clinical trial experts
10.00	Q&A		
10.15	Coffee break		

¹ <http://apps.who.int/medicinedocs/en/m/abstract/Js22083en/>

² https://apps.who.int/iris/bitstream/handle/10665/44412/WHO_TRS_949_eng.pdf?sequence=1

Time	Day 2 - suite – Wednesday, 29 November	Working material	Presenter
10.30	PICO 2: Systematic review and grading of evidence	- Systematic review report	Cochrane Evidence Review Group
11.00	Findings from the qualitative study		Gladys Honnein
11.15	PICO 2: E-t-D: PKDL treatment in East Africa	All the documents referred	E. Akl (Co-Chair)
12.30	Lunch break		
13.30	PICO 2: contd.		Chair, Co-Chair & GDG
15.30	Coffee break		
15.45	PICO 3: Systematic review and grading of evidence		Chair, Co-Chair & GDG
16.00	Findings from the qualitative study		Expert
16.15	PICO 3: E-t-D: VL treatment in East Africa		
17.15	Summary		Chair, Co-Chair

Time	Day 3 – Thursday, 30 November	Working material	Presenter
9.00	PICO 3 (contd.)		Chair, Co-Chair & GDG
10.30	Coffee break		
10.45	PICO 4: Systematic review and grading of evidence	- Systematic review report	Cochrane Evidence Review Group
11.15	Findings from the qualitative study		Gladys Honnein
11.30	PICO 4 E-t-D: VL relapse treatment in South-East Asia	All the documents referred	Chair, Co-Chair & GDG
12.30	Lunch break		
13.30	PICO 4: contd.		Chair, Co-Chair & GDG
15.30	Coffee break		
15.45	PICO 4: contd.		
17.30	Next steps and closing of the meeting		Chair, Co-Chair and WHO

PICO question

PICO question 1:

[What are the efficacy and safety of the different pharmacological treatments for the management of people diagnosed with PKDL in South Asia?](#)

PICO question 2:

[What are the efficacy and safety of the different pharmacological treatments for the management of people diagnosed with PKDL in East Africa?](#)

PICO question 3:

[What are the efficacy and safety of the different pharmacological treatments for the management of non-immunocompromised people diagnosed with primary and relapse visceral leishmaniasis in Eastern Africa?](#)

PICO question 4:

[What are the efficacy and safety of the different pharmacological treatments for the management of non-immunocompromised people diagnosed with a relapse of visceral leishmaniasis in South Asia?](#)